EUDAW Market Analysis
Fundamentals
Updated daily after market closeValuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- —
- P/S (TTM)
- —
- EV/EBITDA
- —
Profitability & growth
- ROE (TTM)
- 0.0%
- Operating margin
- -34.8%
- Revenue growth YoY
- 78.9%
- Dividend yield
- —
- Beta
- 0.59
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About EUDA Health Holdings Limited
Company profileEUDA Health Holdings Limited is an innovative biotechnology company focused on creating advanced therapies for dermatological and chronic health conditions. Leveraging scientific innovation and technology, EUDA is dedicated to addressing significant unmet medical needs with its robust pipeline of transformative products. Guided by a highly experienced leadership team, the company is strategically poised to seize growth opportunities in the dynamic healthcare sector, ultimately striving to enhance patient outcomes and quality of life.
Classification
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 60 KAKI BUKIT PLACE, SINGAPORE, SINGAPORE
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer